222 related articles for article (PubMed ID: 24758181)
1. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Chiu WY; Chien JY; Yang WS; Juang JM; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Lin TC; Yang CY; Kao Yang YH; Lin SJ
Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
4. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Chiu WY; Yang WS; Chien JY; Lee JJ; Tsai KS
PLoS One; 2018; 13(4):e0196419. PubMed ID: 29694412
[TBL] [Abstract][Full Text] [Related]
5. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
[TBL] [Abstract][Full Text] [Related]
6. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
7. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
[TBL] [Abstract][Full Text] [Related]
8. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
9. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
10. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Vestergaard P; Schwartz K; Rejnmark L; Mosekilde L; Pinholt EM
J Oral Maxillofac Surg; 2012 Apr; 70(4):821-9. PubMed ID: 21764202
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
[TBL] [Abstract][Full Text] [Related]
12. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
[TBL] [Abstract][Full Text] [Related]
13. Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study.
Lee JJ; Cheng SJ; Wang JJ; Chiang CP; Chang HH; Chen HM; Kok SH
Head Neck; 2013 Dec; 35(12):1787-95. PubMed ID: 23508560
[TBL] [Abstract][Full Text] [Related]
14. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Ulmner M; Jarnbring F; Törring O
J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
[TBL] [Abstract][Full Text] [Related]
17. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
18. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.
Sedghizadeh PP; Stanley K; Caligiuri M; Hofkes S; Lowry B; Shuler CF
J Am Dent Assoc; 2009 Jan; 140(1):61-6. PubMed ID: 19119168
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
20. Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.
Park JH; Kwoen MJ; Lee JR; Kim KS; Lee HJ; Kim JW; Lee H
Front Endocrinol (Lausanne); 2021; 12():774820. PubMed ID: 34956086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
